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Objectives: To observe the relative role of individual and group-level antimicrobial selective pressure on
subsequent methicillin-resistant Staphylococcus aureus (MRSA) isolation in a university hospital.
Methods: For this purpose, 18 596 patients were included in a retrospective statistical analysis, applying
multilevel modelling with discrete time intervals at the lowest level. Individual-level and hospital group
variables on antimicrobial exposure and MRSA colonization pressure were collected from computerized
databases.
Results: The simultaneous hospital group- and individual-level analysis showed individual exposure to
fluoroquinolones and collective exposure to penicillins to be associated with MRSA isolation after
adjustment for colonization pressure and other potential confounders.
Conclusions: These results support efforts to reduce prescriptions of selected antimicrobial drug
classes such as fluoroquinolones and show the added value of multilevel analysis for research on the
adverse outcomes of antibiotic prescribing.
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Introduction
Recent studies have highlighted the importance of antibiotic
exposure as a significant risk factor for the acquisition and
transmission of methicillin-resistant Staphylococcus aureus
(MRSA).1 However, the effect of this individual-level antibiotic
exposure can be decreased or amplified as a result of an interaction
between the individual and the group effect.2 This group-level
effect (also called ecological effect) may be particularly important
for Gram-positive pathogens, such as MRSA. In a recent article,
Monnet et al.3 have reported that, at a hospital level, use of
antimicrobial drugs may be an important factor in perpetuating a
hospital-wide MRSA outbreak. We have also demonstrated a
relationship between antimicrobial use and MRSA spread at the
hospital unit (HU) level.4 Notwithstanding their many pitfalls,
ecological studies provide a potentially useful function in studies
of infectious agents, because they allow measurement of the global
effect of an exposure. This is important, because the global effects
of antibiotics encompass not just the direct effects on the
individual who receives the antibiotic but also the indirect effects
mediated by effects on transmissibility or on the likelihood of
transmission of susceptible organisms.5 The present study was
specifically designed to determine the relative part of individual-
and group-level (HU) antimicrobial pressure on subsequent
MRSA isolation. For this purpose, we used advanced statistical
multilevel modelling, which takes account of factors at the
individual and group level simultaneously.
Materials and methods
Setting, study period and patients
The Besanc¸on Hospital is a French university-affiliated hospital.
Data for year 2001 were collected for the following departments:
medicine, surgery and adult intensive care. Psychiatric, paediatric and
gynaecology-obstetric units were excluded. All patients admitted for
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more than 48 h were included in the study. For each patient, only the
first hospitalization during the study period and only the time spent in
the HU where the patient was present 48 h after admission were
retained for the analysis.
MRSA status
MRSA-positive patients were defined as patients who had a clinical
specimen (requested for diagnostic work-up) that yielded MRSA and
who were not known to be positive for MRSA during the previous
12 months. Screening samples were not considered for ascertainment
of the MRSA status. Patients in whom MRSA was isolated within
48 h after admission (imported MRSA cases) were excluded.
Data structure
Level 1: Time. The lowest level was that of discrete 24 h time periods
nested within individual patients. The history of each patient in the HU
was treated as a series of discrete 24 h periods, excluding the first 2 days
of hospitalization. For individual colonization pressure and antibiotic
exposure variables, each day of hospitalization was coded as negative
before occurrence and as positive from the first day it occurred to the
last day of the follow-up. Patients without MRSA isolation were
censored at the time of HU discharge or in-hospital death.
Level 2: Individual. Individual patients constituted the second level of
the data. Individual-data variables on age (> or  60 years), sex and
individual MRSA colonization pressure (presence or absence in the
HU of at least one patient known to be positive for MRSA during the
hospitalization) were collected from computerized databases. Indivi-
dual exposure to each of the four antimicrobial classes of interest
defined (see below) was expressed as a binary, time-varying covariate
(exposed/non-exposed on a given day).
Level 3: Hospital unit (HU). The highest level of data was at the HU
level. The HUs were classified into three types: medicine (n = 31),
surgery (n = 17) and intensive care (n = 2). The average antibiotic
use was 718.5 DDD per 1000 patient-days, ranging from 535.4 in
surgical units to 808.6 in medical units and 1517.7 in ICUs.
Antibiotics were grouped into five classes: penicillins, cephalosporins,
fluoroquinolones (96% inactive against MRSA), glycopeptides (100%
active against MRSA) and other antibiotics (including macrolides,
lincosamides, aminoglycosides) with variable activity against MRSA.
The distribution of antibiotic use by class was penicillins, 51.3%;
cephalosporins, 10.9%; fluoroquinolones, 18.6%; glycopeptides,
3.6%; and other antibiotics, 15.6%. We only retained penicillins,
cephalosporins, fluoroquinolones and glycopeptides for the analysis.
The HUs were divided into two categories using the median cut-point
for each of the four retained antimicrobial classes (weak versus high
consumer). In addition, the mean colonization pressure was calculated
for each unit from the ratio of the number of patient-days of MRSA
patients to the total number of patient-days.
Statistical analysis
We analysed data using a multilevel discrete-time logistic regression
model with MRSA ascertainment as binary outcome.6 This approach
allowed us to consider a nested hierarchical structure of the data.
Initially, each variable was tested in a univariate model adjusted for
the time at risk. Second, a reference model was built by introducing
the variables with P < 0.20 in the univariate analysis, with the
exception of antimicrobial exposure. Both individual and collective
antimicrobial exposure variables were simultaneously forced into the
reference model. Modelling was performed using MlwiN V2.0
software.
Results
In 2001, 41 790 patients (excluding re-admissions) were admitted, of
whom 18596 were included in our study. We identified 59 MRSA-
positive patients according to our selection criteria. Characteristics of
the patients are shown in Table 1. In univariate analysis, group-level
MRSA colonization pressure (P = 0.002), group-level penicillin use
(P= 0.001) and individual fluoroquinolone exposure (P< 0.001)were
associated with MRSA isolation. In Figure 1, MRSA isolation is
plotted by individual antibiotic exposure and level of antibiotic use in
the HU. Figure 1(a) suggests a unique increase with the individual
fluoroquinolone exposure regardless of the level of fluoroquinolone
use in the HU. Conversely, Figure 1(b) suggests a unique increase
with high level of penicillin use in the HU regardless of the individual
penicillin exposure.
The simultaneous hospital group- and individual-level analysis
showed individual exposure to fluoroquinolones and collective
exposure to penicillins to be associated with MRSA isolation after
adjustment for colonization pressure and other potential con-
founders (Table 2). For fluoroquinolones, the effect of individual
exposure was not modified when adjusted on collective exposure.
Conversely, for penicillins, the observed collective effect was not
influenced by individual exposure.
Discussion
The results reported here demonstrate a significant association
between antibiotic exposure and subsequent isolation of MRSA in
our hospital. This relationship persists when other identified risk
factors such as age, sex, MRSA colonization pressure and the type
of unit are taken into account. The advanced multilevel analysis
fits the complex structure of the data and allows differentiation
between individual and collective antibiotic exposure for each
antimicrobial class.
Table 1. Characteristics of the patients
Variables
MRSA-negative
patients
MRSA-positive
patients
Number of patients 18 537 59
Mean (SD) age 58 years (20.91) 72 years (16.37)
Percentage of patients
who were men
54.4% 57.6%
Mean (SD) hospitalization
duration in the first unit
7.4 days (9.84) 35.3 days (23.89)
Mean (SD) delay between
admission and MRSA
isolation
16.2 days (4.73)
Percentage of patients who
received at least one
antimicrobial
23.6% 64.4%
Percentage of patients
simultaneously hospitalized
with at least one other
MRSA-positive patient in
the same unit.
48.2% 74.6%
MRSA, methicillin-resistant Staphylococcus aureus.
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Regarding the fluoroquinolone effect, our results are con-
cordant with those of Weber et al.,1 who demonstrated that
this class has a specific individual effect on MRSA. Our
multilevel model shows that this effect is observed regardless of
the amount of fluoroquinolones used at the HU level. It suggests
that the ecological effect of fluoroquinolones reported by
previous studies may just reflect the sum of individual effects.3,4,7
Fluoroquinolones, which are frequently ineffective against
nosocomial MRSA,8 have an excellent tissue diffusion, which
could promote the acquisition of MRSA by eradicating
susceptible microorganisms, such as methicillin-susceptible
Staphylococcus aureus (MSSA). Moreover, Bisognano et al.9
have demonstrated that exposure to subinhibitory levels of
ciprofloxacin results in increased expression of adherence factors
promoting host colonization. It seems that the combination of the
two mechanisms gives a plausible explanation for the specific
effect of fluoroquinolones on MRSA: fluoroquinolone exposure
would promote Staphylococcus aureus colonization while selec-
tively eradicating MSSA strains.
We observed a group-level effect of penicillin use on MRSA
isolation and this could not be explained by an ecological fallacy
because both individual- and group-level antibiotic exposure was
considered using adequate statistical modelling. Thus, an
ecological effect purely explained by the aggregated effect of
individual exposures can be excluded. The observed ecological
effect could be due either to a confounding factor or to a real
effect. Penicillins are the most frequently prescribed antibiotic
class in our hospital, making it possible that an ecological effect
would only manifest above a certain threshold of use.
Some limitations of our study have to be addressed. First, our
findings are supported by data collected in a single hospital. It
would be of interest to apply our multilevel model to other
settings. Second, due to statistical complexity, we used a nested
multilevel model which implies that one level is related to only
one upper level. So, we only retained the first unit-stay for
analysis and consequently did not consider the entire spectrum of
MRSA colonization occurring in our hospital. Third, our
microbiological data, i.e. isolation of MRSA from clinical sample,
were laboratory-based. We did not collect clinical information to
confirm MRSA infection. MRSA screening on admission was
performed for 15% of the patients admitted. So, we have not
evidenced a specific association of antibiotic exposure with
MRSA acquisition or with progression from MRSA colonization
towards infection but an association between antibiotic exposure
and a mix of these two stages.
Finally, our results are consistent with several studies,
supporting a relationship between antimicrobial use, particularly
individual exposure to fluoroquinolones, and MRSA spread.3,4
Interestingly, hospitals in Nordic European countries, with very
low MRSA incidence, use the least fluoroquinolones.10 Our
findings support efforts to further study the effect of implement-
ing programmes to control antibiotic use. To conclude, our
multilevel analysis shows that exploring the problem of
antimicrobial resistance at the individual level or at the collective
level alone will miss either of these aspects of the problem.
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(a) Fluoroquinolones; (b) penicillins.
Table 2. Multilevel (including time) multivariate analysis for
each antimicrobial variable adjusted for sex, individual, MRSA
colonization pressure and type of hospital unit
Individual exposure Group-level exposure
Antibiotic class OR (95% CI)
P
value* OR (95% CI)
P
value*
Penicillins 0.89 (0.49–1.62) 0.79 2.52 (1.15–5.51) 0.03
Fluoroquinolones 2.63 (1.44–4.80) 0.01 0.85 (0.37–1.96) 0.64
Cephalosporins 0.83 (0.38–1.83) 0.71 0.85 (0.39–1.86) 0.61
Glycopeptides 2.01 (0.62–6.53) 0.25 0.99 (0.45–2.20) 0.98
*Wald test.
880
Muller et al.
2. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial
resistance: a population perspective. Emerg Infect Dis 2002; 8: 347–54.
3. Monnet DL, MacKenzie FM, Lopez-Lozano JM et al. Antimicrobial
drug use and methicillin-resistant Staphylococcus aureus, Aberdeen,
1996–2000. Emerg Infect Dis 2004; 10: 1432–41.
4. Muller A, Mauny F, Bertin M et al. Relationship between spread of
methicillin-resistant Staphylococcus aureus and antimicrobial use in a
French university hospital. Clin Infect Dis 2003; 36: 971–8.
5. Harbarth S, Harris AD, Carmeli Y et al. Parallel analysis of
individual and aggregated data on antibiotic exposure and resistance in
gram-negative bacilli. Clin Infect Dis 2001; 33: 1462–8.
6. Goldstein H, Pan H, Bynner J. A flexible procedure for analysing
longitudinal event histories using a multilevel model. Understanding
Statistics 2004; 3: 85–9.
7. MacDougall C, Harpe SE, Powell JP et al. Pseudomonas
aeruginosa, Staphylococcus aureus, and fluoroquinolone use. Emerg
Infect Dis 2005; 11: 1197–204.
8. Thouverez M, Muller A, Hocquet D et al. Relationship between
molecular epidemiology and antibiotic susceptibility of methicillin-
resistant Staphylococcus aureus (MRSA) in a French teaching hospital.
J Med Microbiol 2003; 52: 801–6.
9. Bisognano C, Vaudaux P, Rohner P et al. Induction of fibronectin-
binding proteins and increased adhesion of quinolone-resistant Staphy-
lococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob
Agents Chemother 2000; 44: 1428–37.
10. Muller-Pebody B, Muscat M, Pelle B et al. Increase and change in
pattern of hospital antimicrobial use, Denmark, 1997–2001. J Antimicrob
Chemother 2004; 54: 1122–6.
881
MRSA and antibiotic use
